Chapter 13 PPAR and Pain

International Review of Neurobiology

Volumn 85, Issue , 2009, Pages 165-177

  Maeda, Takehiko ^a   Kishioka, Shiroh ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; DELTA12 PROSTAGLANDIN J2; FIBRIC ACID DERIVATIVE; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PIOGLITAZONE; ROSIGLITAZONE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; HYPERALGESIA; HYPERLIPIDEMIA; INFLAMMATORY DISEASE; MACROPHAGE ACTIVATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NEUROPROTECTION; NOCICEPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; SPINAL CORD INJURY; TRANSCRIPTION REGULATION; VISCERAL PAIN; ANIMAL; HUMAN; IMMUNOLOGY; INFLAMMATION; NEUROGENIC INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION; LIGANDS; NEUROGENIC INFLAMMATION; PAIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA;

EID: 67650046035     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)85013-7     Document Type: Review

References (64)

1. Adachi M., Kurotani R., Morimura K., Shah Y., Sanford M., Madison B.B., Gumucio D.L., Marin H.E., Peters J.M., Young H.A., and Gosnzalez F.J. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55 (2006) 1104-1113
2. Benani A., Heurtaux T., Netter P., and Minn A. Activation of peroxisome proliferator-activated receptor alpha in rat spinal cord after peripheral noxious stimulation. Neurosci. Lett. 369 (2004) 59-63
3. Churi S.B., Abdel-Aleem O.S., Tumber K.K., Scuderi-Porter H., and Taylor B.K. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J. Pain 9 (2008) 639-649
4. Colburn R.W., Rickman A.J., and DeLeo J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. 157 (1999) 289-304
5. Costa B., Comelli F., Bettoni I., Colleoni M., and Giagoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139 (2008) 541-550
6. Cristiano L., Bernardo A., and Ceru M.P. Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J. Neurocytol. 30 (2001) 671-683
7. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., and Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 70 (1998) 1366-1375
8. Culman J., Zhao Y., Gohlke P., and Herdegen T. PPAR-gamma: Therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28 (2007) 244-249
9. Cuzzocrea S., Di Paloa R., Mazzon E., Genovese T., Muia C., Centorrino T., and Caputi A.P. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab. Invest. 84 (2004) 1643-1654
10. Cuzzocrea S., Mazzon E., Di Paola R., Peli A., Bonato A., Britti D., Genovese T., Muia C., Crisafulli C., and Caputi A.P. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J. Leukoc. Biol. 79 (2006) 999-1010
11. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2 (2002) 748-759
12. Delerive P., Furman C., Teissier E., Fruchart J., Duriez P., and Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett. 471 (2000) 34-38
13. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193 (2001) 827-838
14. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
15. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147 (2007) 578-581
16. Dunn S.E., Ousman S.S., Sobel R.A., Zuniga L., Baranzini S.E., Youssef S., Crowell A., Loh J., Oksenberg J., and Steinman L. Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J. Exp. Med. 204 (2007) 321-330
17. Escher P., and Wahli W. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Mutat. Res. 448 (2000) 121-138
18. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 10 (2004) 355-361
19. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 94 (1997) 4312-4317
20. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez De Fonseca F., Rosengarth A., Luecke H., Di Giacomo B., Tarzia G., and Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 (2003) 90-93
21. Gampe Jr. R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., and Xu H.E. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5 (2000) 545-555
22. Genovese T., Mazzon E., Di Paola R., Muia C., Crisafulli C., Malleo G., Esposito E., and Cuzzocrea S. Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein. Immunology 118 (2006) 559-570
23. Gervois P., Torra I.P., Chinetti G., Grotzinger T., Dubois G., Fruchart J.C., Fruchart-Najib J., Leitersdorf E., and Staels B. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol. Endocrinol. 13 (1999) 1535-1549
24. Heneka M.T., Feinstein D., Galea E., Gleichmann M., Wullner U., and Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
25. Hu P., and McLachlan E.M. Distinct functional types of macrophage in dorsal root ganglia and spinal nerves proximal to sciatic and spinal nerve transections in the rat. Exp. Neurol. 184 (2003) 590-605
26. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
27. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., Sagar D.R., Bennett A.J., Alexander S.P., Kendall D.A., Barrett D.A., and Chapman V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55 (2008) 85-93
28. Jin S.X., Zhuang Z.Y., Woolf C.J., and Ji R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 23 (2003) 4017-4022
29. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., and Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
30. Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71 (2003) 315-325
31. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
32. Konturek P.C., Brzozowski T., Kania J., Konturek S.J., Kwiecien S., Pajdo R., and Hahn E.G. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur. J. Pharmacol. 472 (2003) 213-220
33. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
34. LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., and Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319 (2006) 1051-1061
35. Maeda T., Kiguchi N., Kobayashi Y., Ozaki M., and Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J. Pharmacol. Sci. 108 (2008) 341-347
36. Maggi Jr. L.B., Sadeghi H., Weigand C., Scarim A.L., Heitmeier M.R., and Corbett J.A. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49 (2000) 346-355
37. Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131-145
38. Myers R.R., Yamamoto T., Yaksh T.L., and Powell H.C. The role of focal nerve ischemia and Wallerian degeneration in peripheral nerve injury producing hyperesthesia. Anesthesiology 78 (1993) 308-316
39. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
40. Napimoga M.H., Souza G.R., Cunha T.M., Ferrari L.F., Clemente-Napimoga J.T., Parada C.A., Verri Jr. W.A., Cunha F.Q., and Ferreira S.H. 15d-prostaglandin J2 inhibits inflammatory hypernociception: Involvement of peripheral opioid receptor. J. Pharmacol. Exp. Ther. 324 (2008) 313-321
41. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
42. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
43. Oliveira A.C., Bertollo C.M., Rocha L.T., Nascimento Jr. E.B., Costa K.A., and Coelho M.M. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur. J. Pharmacol. 561 (2007) 194-201
44. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., and Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 320 (2007) 1002-1012
45. Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., Richardson J., Willson T.M., Weinberg G., and Feinstein D.L. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168 (2005) 65-75
46. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., and Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 95 (1998) 7614-7619
47. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
48. Russo R., LoVerme J., La Rana G., D'Agostino G., Sasso O., Calignano A., and Piomelli D. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur. J. Pharmacol. 566 (2007) 117-119
49. Sagar D.R., Kendall D.A., and Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 155 (2008) 1297-1306
50. Scholz J., and Woolf C.J. The neuropathic pain triad: Neurons, immune cells and glia. Nat. Neurosci. 10 (2007) 1361-1368
51. Shah Y.M., Morimura K., and Gonzalez F.J. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G657-G666
52. Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., Kadowaki T., Mayumi T., Yura Y., and Kamisaki Y. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur. J. Pharmacol. 448 (2002) 231-238
53. Stoll G., Jander S., and Myers R.R. Degeneration and regeneration of the peripheral nervous system: From Augustus Waller's observations to neuroinflammation. J. Peripher. Nerv. Syst. 7 (2002) 13-27
54. Straus D.S., and Glass C.K. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol. 28 (2007) 551-558
55. Suardiaz M., Estivill-Torrus G., Goicoechea C., and Bilbao A. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133 (2007) 99-110
56. Sweitzer S.M., Hickey W.F., Rutkowski M.D., Pahl J.L., and DeLeo J.A. Focal peripheral nerve injury induces leukocyte trafficking into the central nervous system: Potential relationship to neuropathic pain. Pain 100 (2002) 163-170
57. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
58. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992) 433-439
59. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., and Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem. 273 (1998) 31108-31112
60. Wang X., Miyares R.L., and Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J. Physiol. 564 (2005) 541-547
61. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
62. Woerly G., Honda K., Loyens M., Papin J.P., Auwerx J., Staels B., Capron M., and Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198 (2003) 411-421
63. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M., Kliewer S.A., and Milburn M.V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell. 3 (1999) 397-403
64. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., Oplinger J.A., Kliewer S.A., Gampe Jr. R.T., McKee D.D., Moore J.T., and Willson T.M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 98 (2001) 13919-13924